EDMONTON, Alberta – March 30, 2012 – Fedora Pharmaceuticals, Inc. today announced the Company’s incorporation and in-license of exclusive worldwide rights to a family of beta-lactamase inhibitors (BLIs) discovered by scientists at NAEJA Pharmaceuticals. Fedora plans to develop these BLIs, which are currently in preclinical development, for use in combination with various beta-lactam antibiotics to treat those antibiotic infections currently resistant to therapy.
“The entire Fedora team and I recognize the importance of the work we are conducting to address the growing threat of antibiotic resistance,” stated Christopher Micetich, chief executive officer and founder of Fedora Pharmaceuticals. “In fact, my father, the late Dr. Ronald G. Micetich, lead the team that discovered and developed one of the first BLI, tazobactam in the 1990s. This personal history grants me a sense of personal pride and a drive to succeed in our development and eventual commercialization of the next generation of BLIs, which I expect will provide physicians with a valuable adjunct to antibiotic therapy.”
Fedora Pharmaceuticals is in the lead optimization stage of preclinical development with multiple betalactamase inhibitor molecules. These candidates have shown activity against pathogens containing the four beta-lactamase classes included the metallo-family of beta-lactamase enzymes. Fedora anticipates completing preclinical development, selecting one or more lead compounds and entering IND-enabling studies in 2013.
Antibiotic resistance and beta‑lactamases
Over time, bacteria have evolved a resistance to beta-lactam antibiotics through the production of betalactamases – enzymes that cleave the beta-lactam ring structure that is common to their molecular structure, thereby inhibiting their antibiotic activity. Beta‑lactam antibiotics, which include penicillin derivatives, cephalosporins, monobactams and carbapenems, have broad utility in the treatment of either Gram-negative or Gram-positive bacteria and as such have been estimated to comprise more than half of the antibiotics market worldwide. It is therefore critical that resistance to beta‑lactam antibiotics be addressed.
First-generation beta-lactamase inhibitors, initially introduced in the 1980s, were an important advance and have seen strong market adoption. However, their activity against only one of the four classes of beta-lactamases has limited their potential.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals is developing a family of beta-lactamase inhibitors designed to have activity against pathogens containing all four classes of beta-lactamases. These and potentially other betalactamase inhibitors will be developed by Fedora for use in combination with various beta-lactam antibiotics to treat those antibiotic infections currently resistant to therapy. Fedora Pharmaceuticals is in the lead optimization stage of preclinical development with its first beta-lactamase inhibitor candidates, and anticipates entering IND-enabling studies in 2013. Fedora was founded in 2012 and is headquartered in Edmonton, Alberta, Canada. For more information on the company, please visit www.fedorapharma.com.
Read the article here.